<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99080">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824758</url>
  </required_header>
  <id_info>
    <org_study_id>ESM 0538</org_study_id>
    <nct_id>NCT01824758</nct_id>
  </id_info>
  <brief_title>Effect of Esmolol on Pain Due to Rocuronium</brief_title>
  <official_title>The Effect of Esmolol on Pain Due to Rocuronium Injection Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Etlik Zubeyde Hanim Womens' Health and Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Etlik Zubeyde Hanim Womens' Health and Teaching Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      90 American society of anesthesiology (ASA) physical status I and II patients undergoing
      general anesthesia for elective surgery will be included in the study. Patients will be
      randomized into three groups. Group E will receive esmolol (1 mg/kg), Group IL lidocaine
      (1.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL), followed by a 0.05 mg/kg rocuronium. After
      intravenous induction with propofol, adequate muscle relaxation for intubation will be
      received by 0.5 mg/kg rocuronium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be observed after injection of rocuronium 0.05mg/kg, then immediately asked if
      they have pain in the arm. The response are assessed; discomfort, pain, and withdrawal of
      the hand are recorded and graded using a 4-point scale (none, mild, moderate, or severe).
      After the intubating dose of rocuronium, withdrawal reactions are scored as follows: (a) no
      pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d)
      generalized pain response.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>The injection pain due to rocuronium</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pain will be recorded and graded using a 4-point scale (none, mild, moderate, or severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on  pain due to injection of rocuronium</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Withdrawal reactions are scored as follows: (a) no pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d) generalized pain response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess patient satisfaction</measure>
    <time_frame>1 Month</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Injection Site Irritation</condition>
  <arm_group>
    <arm_group_label>brevibloc (esmolol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group E will receive esmolol (1 mg/kg), Group L lidocaine (1.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aritmal (Lidocaine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group E: esmolol (1 mg/kg) Group L: lidocaine (1.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NaCl 0.9%, 5 ml)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group E: esmolol (1 mg/kg) Group L: lidocaine (1.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Group L lidocaine (1.5 mg/kg), (rocuronium) (0.05mg/kg).</description>
    <arm_group_label>Aritmal (Lidocaine)</arm_group_label>
    <other_name>Aritmal, Jetmonal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)</description>
    <arm_group_label>brevibloc (esmolol)</arm_group_label>
    <other_name>brevibloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rocuronium</intervention_name>
    <description>0.05 mg/kg rocuronium</description>
    <arm_group_label>brevibloc (esmolol)</arm_group_label>
    <arm_group_label>Aritmal (Lidocaine)</arm_group_label>
    <arm_group_label>Placebo (NaCl 0.9%, 5 ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)</description>
    <arm_group_label>Placebo (NaCl 0.9%, 5 ml)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status I and II patients

          -  Undergoing general anesthesia for elective surgery

        Exclusion Criteria:

          -  Known allergy to esmolol or lidocaine

          -  Chronic pain

          -  Pregnancy

          -  Withdrawal of consent by the patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fakelma 05327079113</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diskapi Teaching and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>fatma k. akelma</last_name>
    <phone>905327079113</phone>
    <email>fatmakavak@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>j√ºlide ergil</last_name>
    <phone>905323469216</phone>
    <email>julideergil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diskapi Teaching and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Altindag</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Etlik Zubeyde Hanim Womens' Health and Teaching Hospital</investigator_affiliation>
    <investigator_full_name>Fatma Kavak Akelma</investigator_full_name>
    <investigator_title>Specialist</investigator_title>
  </responsible_party>
  <keyword>esmolol, injection pain, lidocaine, rocuronium</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
